289 related articles for article (PubMed ID: 22158046)
1. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
2. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
3. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
7. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
8. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
9. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
10. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
11. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.
Rea K; Roggiani F; De Cecco L; Raspagliesi F; Carcangiu ML; Nair-Menon J; Bagnoli M; Bortolomai I; Mezzanzanica D; Canevari S; Kourtidis A; Anastasiadis PZ; Tomassetti A
J Exp Clin Cancer Res; 2018 Jul; 37(1):146. PubMed ID: 29996940
[TBL] [Abstract][Full Text] [Related]
13. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
14. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Ren F; Shi H; Zhang G; Zhang R
J Exp Clin Cancer Res; 2013 Aug; 32(1):60. PubMed ID: 23988121
[TBL] [Abstract][Full Text] [Related]
15. Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
Ye J; Chen W; Wu ZY; Zhang JH; Fei H; Zhang LW; Wang YH; Chen YP; Yang XM
Oncol Rep; 2016 Dec; 36(6):3588-3596. PubMed ID: 27779718
[TBL] [Abstract][Full Text] [Related]
16. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.
Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M
Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004
[TBL] [Abstract][Full Text] [Related]
18. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
